IP Library Granted Patent US 7,455,986
Granted Patent B2
US 7,455,986 · App. 11/187,571 · Granted Nov 25, 2008

Heparinase III and methods of specifically cleaving therewith

Assignee: Massachusetts Institute of Technology, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,986
App. No.
11/187,571
Granted
Nov 25, 2008
Kind
B2
Abstract

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Claims (10)

1. A method of cleaving comprising:

contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [α-L-iduronic acid (I) or β-D-glucuronic acid (G)] linked 1, 4 to α-D-hexosamine (H) with a protein comprising a modified heparinase III in vitro, wherein the modified heparinase III has the amino acid sequence of the mature peptide of SEQ ID NO: 2, wherein at least one histidine residue selected from the group consisting of His36, His105, His110, His139, His152, His225, His234, His241, His424, His469, and His539 has been substituted with a residue selected from the group consisting of alanine, serine, tyrosine, threonine, and lysine.

2. The method of claim 1 , wherein the modified heparinase III has at least one substitution at a histidine residue selected from the group consisting of His110, His225 and His241.

3. The method of claim 1 , wherein the modified heparinase III has a substitution at His110.

4. The method of claim 1 , wherein the modified heparinase III has a substitution at His241.

5. The method of claim 1 , wherein the modified heparinase III has a substitution at His225.

6. The method of claim 5 , wherein the His225 is substituted with alanine.

7. The method of claim 1 , wherein the modified heparinase III is in a composition that comprises a pharmaceutically acceptable carrier.

8. The method of claim 1 , wherein the modified heparinase III is immobilized on a solid support.

9. The method of claim 8 , wherein the solid support is a sheet, test strip, membrane, bead, test tube, microplate well or the external surface of a rod.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jun 15, 2011
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026444/0681 →
CONFIRMATORY LICENSE Recorded Mar 23, 2011
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026003/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2005
From: LIU, DONGFANG; POJASEK, KEVIN; SHRIVER, ZACHARY; HOLLEY, KRISTINE; EL-SHABRAWI, YOSUF; VENKATARAMAN, GANESH; SASISEKHARAN, RAM
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 016632/0555 →
Continuity (4)
Division 1029133700 · Nov 8, 2002
Division 0980228500 · Mar 8, 2001
Provisional Application 6018784600 · Mar 8, 2000
Related Publication 20060067928A1 · Mar 30, 2006